Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 46

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 46
---
 may only be called by our Board acting pursuant to a resolution approved by the affirmative majority of the entire Board. Stockholders may not take action by written consent. A vote by the holders of a majority of our outstanding shares
is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our Charter.

Subject to
preferences which may be applicable to any outstanding shares of preferred stock from time to time, holders of Common Stock have equal ratable rights to such dividends as may be declared from time to time by our Board out of funds legally available
therefor. In the event of any liquidation, dissolution or winding-up of affairs, holders of Common Stock will be entitled to share ratably in the remaining assets after provision for payment of amounts owed to
creditors and preferences applicable to any outstanding shares of preferred stock. All outstanding shares of Common Stock are fully paid and nonassessable. Holders of Common Stock do not have preemptive rights.

The rights, preferences and privileges of holders of Common Stock are subject to the rights of the holders of any outstanding shares of
preferred stock.

Preferred Stock

Our Board is authorized to issue up to 5,000,000 shares of preferred stock, par value $0.001 per share, in one or more series, 4,721,470 of
which shares are undesignated, with such designations, rights and preferences as may be determined from time to time by our Board. Accordingly, our Board is empowered, without stockholder approval, to issue preferred stock with dividend,
liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights of the holders of Common Stock.

16

Series A Preferred Stock

Our Board previously established a series of preferred stock designated as Series A Preferred Stock (“Series A Preferred Stock”),
comprising 278,530 shares of preferred stock, of which all shares remain outstanding as of November 3, 2025. Subject to superior rights of any other outstanding preferred stock from time to time each outstanding share of Series A Preferred
Stock is entitled to receive, in preference to Common Stock, cumulative dividends, payable quarterly in arrears, at an annual rate of 3% of $1.00 per share (the “Series A Stated Value”). We have never paid dividends on shares of Common
Stock and we do not intend to do so for the foreseeable future. Series A Preferred Stock does not have any voting rights. In the event of liquidation, each